Actinium Pharmaceuticals, Inc.ATNMEarnings & Financial Report
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing targeted radiotherapies for oncology patients with unmet medical needs, covering hematologic cancers and solid tumors. Its pipeline uses antibody radiation conjugate technology to deliver precise cancer treatment while minimizing harm to healthy tissue.
ATNM Q3 FY2025 Key Financial Metrics
Revenue
$90.0K
Gross Profit
N/A
Operating Profit
$-5.7M
Net Profit
$-5.1M
Gross Margin
N/A
Operating Margin
-6324.4%
Net Margin
-5701.1%
YoY Growth
N/A
EPS
$-0.16
Actinium Pharmaceuticals, Inc. Q3 FY2025 Financial Summary
Actinium Pharmaceuticals, Inc. reported revenue of $90.0K for Q3 FY2025, with a net profit of $-5.1M (up 55.6% YoY) (-5701.1% margin).
Key Financial Metrics
| Total Revenue | $90.0K |
|---|---|
| Net Profit | $-5.1M |
| Gross Margin | N/A |
| Operating Margin | -6324.4% |
| Report Period | Q3 FY2025 |
Actinium Pharmaceuticals, Inc. Annual Revenue by Year
Actinium Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $3.1M).
Actinium Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Actinium Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $90.0K | — | $-5.1M | -5701.1% |
| Q1 FY2024 | $927.0K | +69.5% | $-8.7M | -935.3% |
| Q4 FY2023 | $1.0M | — | N/A | N/A |
| Q3 FY2023 | $1.1M | +2288.9% | $-13.3M | -1235.0% |
| Q2 FY2023 | $461.0K | +924.4% | $-15.2M | -3293.1% |
| Q1 FY2023 | $547.0K | -41.8% | $-11.0M | -2017.7% |
| Q4 FY2022 | $0 | — | $-10.6M | N/A |
| Q3 FY2022 | $45.0K | -80.7% | $-9.5M | -21053.3% |
Income Statement
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $45000 | $0 | $547000 | $461000 | $1.1M | $1.0M | $927000 | $90000 |
| YoY Growth | -80.7% | N/A | -41.8% | 924.4% | 2288.9% | N/A | 69.5% | N/A |
Balance Sheet
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $116.8M | $114.2M | $102.0M | $99.1M | $88.9M | $81.4M | $88.4M | $56.2M |
| Liabilities | $45.6M | $47.7M | $44.8M | $46.0M | $45.4M | $45.1M | $44.5M | $42.4M |
| Equity | $71.3M | $66.5M | $57.2M | $53.1M | $43.6M | $36.4M | $43.9M | $13.8M |
Cash Flow
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.7M | $-7.8M | $-15.1M | $-13.6M | $-11.1M | $-47.3M | $-7.4M | $-6.3M |